查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1671181

糖尿病治療藥的全球市場:市場規模·佔有率·趨勢，產業分析 (各類型·各類藥物·各給藥途徑·各流通管道·各地區)，未來預測 (2025年～2034年)

Diabetes Drug Market Size, Share, Trends, Industry Analysis Report: By Type, Drug Class, Route of Administration, Distribution Channel, and Region - Market Forecast, 2025-2034
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，糖尿病藥物市場預計到 2034 年將達到 1,637.9 億美元。該報告提供了有關當前市場動態的詳細見解，並對未來市場成長進行了分析。

糖尿病藥物市場的成長歸因於全球糖尿病盛行率的上升，尤其是第 2 型糖尿病，這是由於人口老化、久坐的生活方式和肥胖率上升等因素造成的。關鍵推動因素包括藥物配方的進步、GLP-1 受體激動劑和 SGLT-2 抑制劑等新型治療劑的引入，以及對心血管和腎臟併發症等合併症的管理日益關注。在糖尿病治療藥物市場的發展中，糖尿病盛行率不斷上升的新興市場以及聯合療法和個人化醫療的開發都存在著商機。

影響市場的主要趨勢包括採用數位健康技術來更好地管理疾病、增加生物相似藥的使用以及注重非侵​​入性治療。總體而言，隨著醫療保健系統不斷發展以滿足對有效且便利的糖尿病管理解決方案日益增長的需求，市場預計將繼續擴大。

糖尿病藥物市場：分析概述

按類型劃分，2 型糖尿病佔糖尿病治療市場銷售額的很大佔有率，並且由於肥胖率上升和人口老化而經歷高速增長。受胰島素治療和胰島素輸送系統進步的推動，這一領域持續成長。

根據給藥途徑，口服藥物因其便利性和廣泛接受度而佔據糖尿病藥物市場佔有率的主導地位，尤其是二甲雙胍和 SGLT-2 抑制劑等藥物。靜脈注射部分雖然佔據最小的市場佔有率，但正在穩步增長，特別是由於胰島素幫浦的使用和專門的醫院護理。

雖然胰島素繼續佔據主導地位，特別是在第 1 型糖尿病的治療中，但 SGLT-2 抑制劑是成長最快的一類藥物，這得益於其在心血管和腎臟保護方面的額外益處，特別是在 2 型糖尿病的管理中。

受糖尿病高盛行率和先進的醫療保健基礎設施的推動，北美佔據最大的市場佔有率。同時，亞太地區是成長最快的地區，這得益於糖尿病患者數量的增加和醫療保健機會的改善。

糖尿病藥物市場的主要參與者包括諾和諾德、賽諾菲、禮來、默克和勃林格殷格翰等大型製藥公司。這些公司積極致力於開發、製造和行銷各種糖尿病治療藥物，包括胰島素治療藥物、GLP-1 受體激動劑和 SGLT-2 抑制劑。

目錄

第1章 簡介

第2章 摘要整理

第3章 分析方法

第4章 全球糖尿病治療藥市場洞察

  • 市場概述
  • 糖尿病治療藥的市場動態
    • 促進因素和機會
      • GLP-1受體激動劑的採用率不斷提高
      • 向個人化糖尿病照護過渡
    • 阻礙因素和課題
      • 糖尿病藥物成本高昂
  • 大環境分析
  • 糖尿病治療藥市場趨勢
  • 價值鏈分析
  • COVID-19影響分析

第5章 全球糖尿病治療藥市場:各類型

  • 主要的分析結果
  • 簡介
  • 第一型
  • 2型

第6章 全球糖尿病治療藥市場:各給藥途徑

  • 主要的分析結果
  • 簡介
  • 口服
  • 靜脈內

第7章 全球糖尿病治療藥市場:各類藥物

  • 主要調查結果
  • 簡介
  • 胰島素
  • 過敏反應劑
  • SGLT-2抑制劑
  • α-葡萄糖苷酶抑制劑

第8章 全球糖尿病治療藥市場:各終端用戶

  • 主要的分析結果
  • 簡介
  • 醫院·診所
  • 門診病人診所

第9章 全球糖尿病治療藥市場:各地區

  • 主要的分析結果
  • 簡介
    • 糖尿病治療藥市場評估:各地區 (2020～2034年)
  • 北美
    • 北美:各類型 (2020～2034年)
    • 北美:各給藥途徑 (2020～2034年)
    • 北美:各類藥物 (2020～2034年)
    • 北美:各終端用戶 (2020～2034年)
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲:各類型 (2020～2034年)
    • 歐洲:各給藥途徑 (2020～2034年)
    • 歐洲:各類藥物 (2020～2034年)
    • 歐洲:各終端用戶 (2020～2034年)
    • 英國
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 荷蘭
    • 俄羅斯
    • 其他歐洲
  • 亞太地區
    • 亞太地區:各類型 (2020～2034年)
    • 亞太地區:各給藥途徑 (2020～2034年)
    • 亞太地區:各類藥物 (2020～2034年)
    • 亞太地區:各終端用戶 (2020～2034年)
    • 中國
    • 印度
    • 馬來西亞
    • 日本
    • 印尼
    • 韓國
    • 澳洲
    • 其他亞太地區
  • 中東·非洲
    • 中東·非洲:各類型 (2020～2034年)
    • 中東·非洲:各給藥途徑 (2020～2034年)
    • 中東·非洲:各類藥物 (2020～2034年)
    • 中東·非洲:各終端用戶 (2020～2034年)
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 南非
    • 其他中東·非洲
  • 南美
    • 南美:各類型 (2020～2034年)
    • 南美:各給藥途徑 (2020～2034年)
    • 南美:各類藥物 (2020～2034年)
    • 南美:各終端用戶 (2020～2034年)
    • 墨西哥
    • 巴西
    • 阿根廷
    • 其他南美國家

第10章 競爭情形

  • 事業擴大·企業收購的分析
    • 事業擴大
    • 企業收購
  • 聯盟/合作/協定/公開

第11章 企業簡介

  • Novo Nordisk
  • Sanofi
  • Eli Lilly
  • Merck
  • Boehringer Ingelheim
  • AstraZeneca
  • Johnson & Johnson
  • Novartis
  • Bayer
  • GlaxoSmithKline
Product Code: PM1327

The diabetes drug market size is expected to reach USD 163.79 billion by 2034, according to a new study by Polaris Market Research. The report "Diabetes Drug Market Size, Share, Trends, Industry Analysis Report: By Type (Type 1 and Type 2), Drug Class, Route of Administration, Distribution Channel, and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa) - Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The diabetes drug market growth is attributed to the rising global prevalence of diabetes, particularly type 2 diabetes, due to factors such as aging populations, sedentary lifestyles, and increasing obesity rates. Key drivers include advancements in drug formulations, the introduction of new therapies such as GLP-1 receptor agonists and SGLT-2 inhibitors, and an increasing focus on managing comorbidities such as cardiovascular disease and renal complications. Diabetes drug market opportunities exist in emerging markets where the prevalence of diabetes is rising, as well as in the development of combination therapies and personalized medicine.

Key trends influencing the market include the adoption of digital health technologies for better disease management, the rise in use of biosimilars, and an emphasis on noninvasive treatments. Overall, the market is expected to continue expanding as healthcare systems evolve to address the growing demand for effective and convenient diabetes management solutions.

Diabetes Drug Market Report Highlights

Based on type, the type-2 diabetes holds a larger share of the diabetes drug market revenue and is experiencing a higher growth, driven by rising obesity rates and an aging population. The segment continues to grow, supported by advancements in insulin therapies and insulin delivery systems.

The oral administration segment, based on route of administration, dominates the diabetes drug market share due to its convenience and wide acceptance, particularly with drugs such as metformin and SGLT-2 inhibitors. The intravenous segment, while holding the smallest market share, is growing steadily, particularly due to the use of insulin pumps and specialized treatments in hospitals.

Based on drug class, the insulin segment remains the dominant segment, especially in type-1 diabetes treatment, but SGLT-2 inhibitors is the fastest-growing segment, driven by their additional benefits in cardiovascular and renal protection, especially in type-2 diabetes management.

North America holds the largest market share, driven by high diabetes prevalence and advanced healthcare infrastructure, whereas Asia Pacific is the fastest-growing region, fueled by rising diabetes cases and improving healthcare access.

A few key players in the diabetes drug market include major pharmaceutical companies such as Novo Nordisk, Sanofi, Eli Lilly, Merck, and Boehringer Ingelheim. These companies are actively involved in the development, production, and distribution of a wide range of diabetes treatments, including insulin therapies, GLP-1 receptor agonists, and SGLT-2 inhibitors.

Polaris Market Research has segmented the diabetes drug market report on the basis of type, route of administration, drug class, distribution channel, and region:

By Type Outlook (Revenue - USD Billion, 2020-2034)

  • Type-1
  • Type-2

By Administration Outlook (Revenue - USD Billion, 2020-2034)

  • Oral
  • Intravenous
  • Subcutaneous

By Drug Class Outlook (Revenue - USD Billion, 2020-2034)

  • Insulin
  • Sensitizers
  • SGLT-2 Inhibitors
  • Alpha-Glucosidase Inhibitors
  • Others
  • By Distribution Channel (Revenue - USD Billion, 2020-2034)
  • Retail Pharmacies
  • Online Pharmacies
  • Hospital Pharmacies

By Regional Outlook (Revenue - USD Billion, 2020-2034)

  • North America
  • US
  • Canada
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
  • Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
  • Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Diabetes Drugs Market Insights

  • 4.1. Diabetes Drugs Market - Market Snapshot
  • 4.2. Diabetes Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing Adoption of GLP-1 Receptor Agonists
      • 4.2.1.2. Shift Towards Personalized Diabetes Treatments
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. High Cost of Diabetes Medications
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Diabetes Drugs Market Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Diabetes Drugs Market, by Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • 5.3. Type-1
    • 5.3.1. Global Diabetes Drugs Market, by Type-1, by Region, 2020-2034 (USD Billion)
  • 5.4. Type-2
    • 5.4.1. Global Diabetes Drugs Market, by Type-2, by Region, 2020-2034 (USD Billion)

6. Global Diabetes Drugs Market, by Administration

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • 6.3. Oral
    • 6.3.1. Global Diabetes Drugs Market, by Oral, by Region, 2020-2034 (USD Billion)
  • 6.4. Intravenous
    • 6.4.1. Global Diabetes Drugs Market, by Intravenous, by Region, 2020-2034 (USD Billion)

7. Global Diabetes Drugs Market, by Drug Class

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • 7.3. Insulin
    • 7.3.1. Global Diabetes Drugs Market, by Insulin, by Region, 2020-2034 (USD Billion)
  • 7.4. Sensitizers
    • 7.4.1. Global Diabetes Drugs Market, by Sensitizers, by Region, 2020-2034 (USD Billion)
  • 7.5. SGLT-2 Inhibitors
    • 7.5.1. Global Diabetes Drugs Market, by SGLT-2 Inhibitors, by Region, 2020-2034 (USD Billion)
  • 7.6. Alpha-Glucosidase Inhibitors
    • 7.6.1. Global Diabetes Drugs Market, by Alpha-Glucosidase Inhibitors, by Region, 2020-2034 (USD Billion)

8. Global Diabetes Drugs Market, by End Users

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 8.3. Hospital & Clinics
    • 8.3.1. Global Diabetes Drugs Market, by Hospital & Clinics, by Region, 2020-2034 (USD Billion)
  • 8.4. Ambulatory Clinics
    • 8.4.1. Global Diabetes Drugs Market, by Ambulatory Clinics, by Region, 2020-2034 (USD Billion)

9. Global Diabetes Drugs Market, by Geography

  • 9.1. Key Findings
  • 9.2. Introduction
    • 9.2.1. Diabetes Drugs Market Assessment, By Geography, 2020-2034 (USD Billion)
  • 9.3. Diabetes Drugs Market - North America
    • 9.3.1. North America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.3.2. North America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.3.3. North America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.3.4. North America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.3.5. Diabetes Drugs Market - US
      • 9.3.5.1. US: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.3.5.2. US: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.3.5.3. US: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.3.5.4. US: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.3.6. Diabetes Drugs Market - Canada
      • 9.3.6.1. Canada: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.3.6.2. Canada: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.3.6.3. Canada: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.3.6.4. Canada: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.4. Diabetes Drugs Market - Europe
    • 9.4.1. Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.4.2. Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.4.3. Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.4.4. Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.5. Diabetes Drugs Market - UK
      • 9.4.5.1. UK: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.5.2. UK: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.5.3. UK: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.5.4. UK: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.6. Diabetes Drugs Market - France
      • 9.4.6.1. France: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.6.2. France: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.6.3. France: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.6.4. France: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.7. Diabetes Drugs Market - Germany
      • 9.4.7.1. Germany: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.7.2. Germany: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.7.3. Germany: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.7.4. Germany: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.8. Diabetes Drugs Market - Italy
      • 9.4.8.1. Italy: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.8.2. Italy: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.8.3. Italy: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.8.4. Italy: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.9. Diabetes Drugs Market - Spain
      • 9.4.9.1. Spain: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.9.2. Spain: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.9.3. Spain: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.9.4. Spain: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.10. Diabetes Drugs Market - Netherlands
      • 9.4.10.1. Netherlands: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.10.2. Netherlands: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.10.3. Netherlands: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.10.4. Netherlands: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.11. Diabetes Drugs Market - Russia
      • 9.4.11.1. Russia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.11.2. Russia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.11.3. Russia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.11.4. Russia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.4.12. Diabetes Drugs Market - Rest of Europe
      • 9.4.12.1. Rest of Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.4.12.2. Rest of Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.4.12.3. Rest of Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.4.12.4. Rest of Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.5. Diabetes Drugs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.5.2. Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.5.3. Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.5.4. Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.5. Diabetes Drugs Market - China
      • 9.5.5.1. China: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.5.2. China: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.5.3. China: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.5.4. China: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.6. Diabetes Drugs Market - India
      • 9.5.6.1. India: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.6.2. India: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.6.3. India: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.6.4. India: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.7. Diabetes Drugs Market - Malaysia
      • 9.5.7.1. Malaysia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.7.2. Malaysia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.7.3. Malaysia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.7.4. Malaysia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.8. Diabetes Drugs Market - Japan
      • 9.5.8.1. Japan: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.8.2. Japan: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.8.3. Japan: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.8.4. Japan: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.9. Diabetes Drugs Market - Indonesia
      • 9.5.9.1. Indonesia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.9.2. Indonesia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.9.3. Indonesia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.9.4. Indonesia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.10. Diabetes Drugs Market - South Korea
      • 9.5.10.1. South Korea: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.10.2. South Korea: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.10.3. South Korea: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.10.4. South Korea: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.11. Diabetes Drugs Market - Australia
      • 9.5.11.1. Australia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.11.2. Australia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.11.3. Australia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.11.4. Australia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.5.12. Diabetes Drugs Market - Rest of Asia Pacific
      • 9.5.12.1. Rest of Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.5.12.2. Rest of Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.5.12.3. Rest of Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.5.12.4. Rest of Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.6. Diabetes Drugs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.6.2. Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.6.3. Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.6.4. Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.6.5. Diabetes Drugs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.6.6. Diabetes Drugs Market - UAE
      • 9.6.6.1. UAE: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.6.6.2. UAE: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.6.6.3. UAE: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.6.6.4. UAE: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.6.7. Diabetes Drugs Market - Israel
      • 9.6.7.1. Israel: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.6.7.2. Israel: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.6.7.3. Israel: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.6.7.4. Israel: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.6.8. Diabetes Drugs Market - South Africa
      • 9.6.8.1. South Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.6.8.2. South Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.6.8.3. South Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.6.8.4. South Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.6.9. Diabetes Drugs Market - Rest of Middle East & Africa
      • 9.6.9.1. Rest of Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.6.9.2. Rest of Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.6.9.3. Rest of Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.6.9.4. Rest of Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • 9.7. Diabetes Drugs Market - Latin America
    • 9.7.1. Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
    • 9.7.2. Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
    • 9.7.3. Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
    • 9.7.4. Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.7.5. Diabetes Drugs Market - Mexico
      • 9.7.5.1. Mexico: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.7.5.2. Mexico: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.7.5.3. Mexico: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.7.5.4. Mexico: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.7.6. Diabetes Drugs Market - Brazil
      • 9.7.6.1. Brazil: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.7.6.2. Brazil: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.7.6.3. Brazil: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.7.6.4. Brazil: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.7.7. Diabetes Drugs Market - Argentina
      • 9.7.7.1. Argentina: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.7.7.2. Argentina: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.7.7.3. Argentina: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.7.7.4. Argentina: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
    • 9.7.8. Diabetes Drugs Market - Rest of Latin America
      • 9.7.8.1. Rest of Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
      • 9.7.8.2. Rest of Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
      • 9.7.8.3. Rest of Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
      • 9.7.8.4. Rest of Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Novo Nordisk
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Sanofi
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. Eli Lilly
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Merck
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. Boehringer Ingelheim
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. AstraZeneca
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Johnson & Johnson
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. Novartis
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Bayer
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. GlaxoSmithKline
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development

List of Tables:

  • Table 1 Global Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 2 Global Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 3 Global Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 4 Global Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 5 North America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 6 North America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 7 North America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 8 North America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 9 U.S.: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 10 U.S.: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 11 U.S.: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 12 U.S.: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 13 Canada: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 14 Canada: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 15 Canada: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 16 Canada: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 17 Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 18 Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 19 Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 20 Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 21 UK: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 22 UK: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 23 UK: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 24 UK: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 25 France: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 26 France: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 27 France: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 28 France: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 29 Germany: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 30 Germany: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 31 Germany: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 32 Germany: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 33 Italy: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 34 Italy: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 35 Italy: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 36 Italy: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 37 Spain: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 38 Spain: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 39 Spain: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 40 Spain: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 41 Netherlands: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 42 Netherlands: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 43 Netherlands: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 44 Netherlands: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 45 Russia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 46 Russia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 47 Russia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 48 Russia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 49 Rest of Europe: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 50 Rest of Europe: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 51 Rest of Europe: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 52 Rest of Europe: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 53 Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 54 Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 55 Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 56 Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 57 China: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 58 China: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 59 China: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 60 China: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 61 India: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 62 India: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 63 India: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 64 India: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 65 Malaysia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 66 Malaysia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 67 Malaysia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 68 Malaysia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 69 Japan: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 70 Japan: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 71 Japan: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 72 Japan: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 73 Indonesia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 74 Indonesia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 75 Indonesia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 76 Indonesia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 77 South Korea: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 78 South Korea: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 79 South Korea: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 80 South Korea: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 81 Australia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 82 Australia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 83 Australia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 84 Australia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 85 Rest of Asia Pacific: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 86 Rest of Asia Pacific: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 87 Rest of Asia Pacific: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 88 Rest of Asia Pacific: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 89 Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 90 Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 91 Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 92 Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 93 Saudi Arabia: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 94 Saudi Arabia: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 95 Saudi Arabia: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 96 Saudi Arabia: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 97 UAE: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 98 UAE: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 99 UAE: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 100 UAE: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 101 Israel: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 102 Israel: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 103 Israel: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 104 Israel: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 105 South Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 106 South Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 107 South Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 108 South Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 109 Rest of Middle East & Africa: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 110 Rest of Middle East & Africa: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 111 Rest of Middle East & Africa: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 112 Rest of Middle East & Africa: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 113 Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 114 Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 115 Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 116 Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 117 Mexico: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 118 Mexico: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 119 Mexico: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 120 Mexico: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 121 Brazil: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 122 Brazil: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 123 Brazil: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 124 Brazil: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 125 Argentina: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 126 Argentina: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 127 Argentina: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 128 Argentina: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)
  • Table 129 Rest of Latin America: Diabetes Drugs Market, by Type, 2020-2034 (USD Billion)
  • Table 130 Rest of Latin America: Diabetes Drugs Market, by Administration, 2020-2034 (USD Billion)
  • Table 131 Rest of Latin America: Diabetes Drugs Market, by Drug Class, 2020-2034 (USD Billion)
  • Table 132 Rest of Latin America: Diabetes Drugs Market, by End Users, 2020-2034 (USD Billion)

List of Figures:

  • Figure 1. Global Diabetes Drugs Market, 2020-2034 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Price
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Type
  • Figure 7. Global Diabetes Drugs Market, by Type, 2024 & 2034 (USD Billion)
  • Figure 8. Market by Administration
  • Figure 9. Global Diabetes Drugs Market, by Administration, 2024 & 2034 (USD Billion)
  • Figure 10. Market by Drug Class
  • Figure 11. Global Diabetes Drugs Market, by Drug Class, 2024 & 2034 (USD Billion)
  • Figure 12. Market by End Users
  • Figure 13. Global Diabetes Drugs Market, by End Users, 2024 & 2034 (USD Billion)